donepezil has been researched along with Dizzyness in 2 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sustained-release, high-dose (23 mg/d) donepezil has been approved for treatment of moderate to severe Alzheimer disease (AD)." | 9.24 | Adverse Events With Sustained-Release Donepezil in Alzheimer Disease: Relation to Body Mass Index. ( Bae, JN; Carroll, BJ; Han, C; Jung, YE; Kang, HS; Kim, BJ; Kim, BS; Kim, DK; Kim, JL; Kim, KW; Kim, SG; Kim, SY; Kim, YH; Lee, C; Lee, DW; Lee, JY; Lee, K; Lee, SY; Lee, YM; Moon, SW; Myung, W; Ryu, SH; Shin, IS; Yu, H, 2017) |
| "Sustained-release, high-dose (23 mg/d) donepezil has been approved for treatment of moderate to severe Alzheimer disease (AD)." | 5.24 | Adverse Events With Sustained-Release Donepezil in Alzheimer Disease: Relation to Body Mass Index. ( Bae, JN; Carroll, BJ; Han, C; Jung, YE; Kang, HS; Kim, BJ; Kim, BS; Kim, DK; Kim, JL; Kim, KW; Kim, SG; Kim, SY; Kim, YH; Lee, C; Lee, DW; Lee, JY; Lee, K; Lee, SY; Lee, YM; Moon, SW; Myung, W; Ryu, SH; Shin, IS; Yu, H, 2017) |
| "(1) Donepezil can reduce memory loss, dry mouth, and constipation in nongeriatric affective patients, but may trigger mania; and (2) long-term follow-up will reveal the predictive value for dementia of donepezil's memory restoration in nongeriatric subjects." | 5.09 | Donepezil for psychotropic-induced memory loss. ( Comas-Díaz, L; Jacobsen, FM, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, C | 1 |
| Lee, K | 1 |
| Yu, H | 1 |
| Ryu, SH | 1 |
| Moon, SW | 1 |
| Han, C | 1 |
| Lee, JY | 1 |
| Lee, YM | 1 |
| Kim, SG | 1 |
| Kim, KW | 1 |
| Lee, DW | 1 |
| Kim, SY | 1 |
| Lee, SY | 1 |
| Bae, JN | 1 |
| Jung, YE | 1 |
| Kim, JL | 1 |
| Kim, BS | 1 |
| Shin, IS | 1 |
| Kim, YH | 1 |
| Kim, BJ | 1 |
| Kang, HS | 1 |
| Myung, W | 1 |
| Carroll, BJ | 1 |
| Kim, DK | 1 |
| Jacobsen, FM | 1 |
| Comas-Díaz, L | 1 |
2 trials available for donepezil and Dizzyness
| Article | Year |
|---|---|
Adverse Events With Sustained-Release Donepezil in Alzheimer Disease: Relation to Body Mass Index.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Body Mass Index; Body Weight; Chol | 2017 |
Donepezil for psychotropic-induced memory loss.
Topics: Adult; Ambulatory Care; Cholinesterase Inhibitors; Constipation; Depressive Disorder; Diarrhea; Dizz | 1999 |